Affinage

SETDB2

Histone-lysine N-methyltransferase SETDB2 · UniProt Q96T68

Length
719 aa
Mass
81.9 kDa
Annotated
2026-04-28
34 papers in source corpus 28 papers cited in narrative 28 extracted findings

Mechanistic narrative

Synthesis pass · prose summary of the discoveries below

SETDB2 is a histone H3 lysine 9 trimethyltransferase that functions as a central epigenetic silencer of inflammatory, metabolic, and developmental gene programs. It deposits H3K9me3 at target gene promoters—including NF-κB-driven inflammatory cytokines (Cxcl1, Il1b, Tnf, Il6), TIMP1-3, NRF2, SMAD3, CDKN2C, TFRC, IDE, SRSF1, and ALPK1—to repress transcription, and its expression is induced by type I interferon signaling through the JAK1/STAT3 pathway, establishing SETDB2 as the principal epigenetic brake governing macrophage inflammatory-to-reparative transitions and trained immunity (PMID:25419628, PMID:31350176, PMID:34479991, PMID:37325923). Beyond catalytic H3K9 trimethylation, SETDB2 possesses methyltransferase-independent functions: it promotes APC/C-dependent CYCLIN B1 degradation during mitosis through interaction with BUBR1, and it positively regulates glycolytic and inflammatory enhancer-promoter looping independently of its SET domain activity (PMID:38151757, PMID:40166182). Its annotated methyl-CpG-binding domain does not bind DNA but instead serves as a protein–protein interaction module, mediating interactions with partners including C11orf46, STAT3, and RELA, the latter interaction being competitively modulated by STAT3 to fine-tune NF-κB target gene accessibility (PMID:38458157, PMID:39435663).

Mechanistic history

Synthesis pass · year-by-year structured walk · 11 steps
  1. 2001 Low

    Initial identification of SETDB2 as a SET-domain and MBD-containing gene at 13q14 raised the hypothesis that it was a methylation-associated transcriptional regulator, but no functional data existed.

    Evidence Sequence analysis and domain prediction from chromosome 13q14 gene isolation

    PMID:11306461

    Open questions at the time
    • No enzymatic or functional assay performed; domain assignments were purely computational
    • MBD domain function was assumed to be DNA-binding without validation
    • No expression or localization data
  2. 2010 High

    The first demonstration that SETDB2 is an active H3K9 trimethyltransferase established its enzymatic identity and linked it to heterochromatin maintenance, HP1 recruitment, and chromosome segregation, answering the fundamental question of what the SET domain does.

    Evidence In vitro methyltransferase assay, ChIP at repeats and centromeres, siRNA knockdown with mitosis/CENP-protein phenotype

    PMID:20404330

    Open questions at the time
    • No genome-wide identification of target loci beyond repetitive elements
    • Relationship to gene-specific transcriptional silencing not yet tested
  3. 2010 High

    Parallel work in zebrafish revealed that Setdb2 controls body axis patterning by repressing fgf8, establishing the principle that SETDB2 silences specific developmental signaling genes—not just repetitive elements.

    Evidence Morpholino knockdown, genetic epistasis with dominant-negative FGFR and fgf8 MO, in situ hybridization in zebrafish

    PMID:20133783

    Open questions at the time
    • Whether H3K9me3 deposition at the fgf8 locus was shown directly was not reported
    • Relevance to mammalian development unclear
  4. 2014 High

    Discovery that type I IFN signaling induces Setdb2 during influenza infection, and that Setdb2 then deposits H3K9me3 at NF-κB target gene promoters (Cxcl1), revealed SETDB2 as the mechanistic link between antiviral interferon responses and suppression of antibacterial NF-κB-driven inflammation.

    Evidence ChIP for Setdb2 and H3K9me3 at Cxcl1 promoter, gene-trap hypomorphic mouse, bacterial superinfection model

    PMID:25419628

    Open questions at the time
    • Upstream signaling intermediates (JAK/STAT) not yet dissected
    • Genome-wide scope of NF-κB target silencing unknown
  5. 2016 High

    SETDB2 was found to function as a coactivator of glucocorticoid receptor-mediated transcription through facilitating enhancer-promoter looping, revealing a transcriptional activation role distinct from its canonical repressive H3K9me3 activity.

    Evidence ChIP, chromatin conformation capture, siRNA knockdown in liver, ob/ob mouse metabolic phenotype

    PMID:27568546

    Open questions at the time
    • Whether coactivation is SET-domain-dependent or independent was not tested
    • Generality beyond GR-regulated liver genes unknown
  6. 2018 High

    Identification of SETDB2 as a direct transcriptional target of the leukemic fusion protein E2A-PBX1 that silences CDKN2C via H3K9me3 connected SETDB2 to cell-cycle dysregulation in cancer and suggested it is co-opted by oncogenic transcription factors.

    Evidence ChIP for E2A-PBX1 at SETDB2 locus, ChIP for H3K9me3 at CDKN2C promoter, shRNA KD, in vivo leukemia models

    PMID:29694893

    Open questions at the time
    • Generality to other leukemia subtypes not established
    • Direct structural interaction between E2A-PBX1 and SETDB2 promoter elements uncharacterized
  7. 2019 High

    Myeloid-specific SETDB2 deletion showed that SETDB2 is required for the inflammatory-to-reparative macrophage transition during wound healing, operating through H3K9me3 at NF-κB binding sites, establishing SETDB2 as the master epigenetic switch of macrophage plasticity.

    Evidence Myeloid-specific conditional KO mouse, ChIP for H3K9me3 at NF-κB sites, wound healing assays

    PMID:31350176

    Open questions at the time
    • Direct physical interaction with NF-κB subunits not yet shown
    • Whether SETDB2 also regulates reparative gene activation was unclear
  8. 2021 High

    Dissection of the IFNβ–JAK1/STAT3–SETDB2 signaling axis in coronavirus infection defined the upstream pathway that controls SETDB2 expression and connected SETDB2 loss to hyperinflammation in COVID-19 macrophages.

    Evidence Myeloid-specific SETDB2 KO, ChIP, JAK/STAT pharmacologic inhibition, human monocytes with SARS-CoV-2

    PMID:34479991

    Open questions at the time
    • Whether STAT3 directly binds the SETDB2 promoter or acts indirectly was not resolved at this point
  9. 2023 High

    Discovery that SETDB2 silences TIMP1-3 in aortic macrophages, unleashing MMP activity and driving abdominal aortic aneurysm, extended the target gene repertoire beyond cytokines to extracellular matrix regulators and demonstrated that SETDB2's repressive activity can be pathogenic in vascular disease.

    Evidence scRNA-seq of human AAA tissue, myeloid conditional KO mouse, ChIP at TIMP1-3 promoters, Tofacitinib treatment

    PMID:37325923

    Open questions at the time
    • How SETDB2 is selectively recruited to TIMP loci versus cytokine loci is unknown
    • Whether SETDB2 interacts with MMP promoters directly was not tested
  10. 2024 High

    Three contemporaneous studies resolved distinct non-catalytic functions: the MBD domain was shown by crystallography to be a protein-protein interaction module (not a DNA-binding domain), STAT3 was identified as a binding partner that competes with RELA for SETDB2 interaction modulating NF-κB access, and SETDB2 was found to promote CYCLIN B1 degradation through BUBR1 independently of methyltransferase activity.

    Evidence Crystal structure of MBD domain with C11orf46 (PMID:38458157); ATAC-seq/Co-IP for STAT3/SETDB2/RELA in KO macrophages (PMID:39435663); Co-IP of SETDB2/BUBR1/CDC20/APC/C with catalytic-dead mutant (PMID:38151757)

    PMID:38151757 PMID:38458157 PMID:39435663

    Open questions at the time
    • Full-length SETDB2 structure is unavailable
    • Whether STAT3 and RELA bind SETDB2 at the same interface is unresolved
    • Whether BUBR1-dependent mitotic function is relevant in vivo beyond cell lines is untested
  11. 2025 Medium

    Recent studies expanded the target gene repertoire to SMAD3 in podocytes, IDE in trigeminal neurons, TFRC in esophageal cancer, and SRSF1 in hepatocellular carcinoma macrophages, and demonstrated that SETDB2 also regulates trained immunity through a dual mechanism involving catalytic-dependent promoter silencing and catalytic-independent enhancer-promoter looping.

    Evidence ChIP at Smad3/IDE/TFRC/SRSF1 promoters with KO/KD models (PMID:41316884, PMID:41880325, PMID:40645600, PMID:41946995); enzymatic-dead mutant with ChIP-seq and chromatin conformation in β-glucan/oxLDL training models (PMID:40166182)

    PMID:40166182 PMID:40645600 PMID:41316884 PMID:41880325 PMID:41946995

    Open questions at the time
    • Genome-wide catalog of catalytic-dependent vs. catalytic-independent targets is incomplete
    • How SETDB2 is recruited to specific promoters in the absence of known sequence-specific DNA binding remains unexplained
    • Whether non-histone substrate methylation (e.g., ΔNp63α) shares the same catalytic mechanism as H3K9 trimethylation is structurally uncharacterized

Open questions

Synthesis pass · forward-looking unresolved questions
  • The mechanism by which SETDB2 is recruited to specific genomic loci—given that its MBD domain does not bind DNA—remains a central unresolved question; no sequence-specific DNA-binding activity has been identified, and the full repertoire of recruiting transcription factors and chromatin readers is unknown.
  • No locus-specific recruitment mechanism defined beyond upstream transcription factor induction
  • Full-length structural model is unavailable
  • Relative physiological importance of catalytic vs. non-catalytic functions in vivo is undefined

Mechanism profile

Synthesis pass · controlled-vocabulary classification · explore literature graph →
Molecular activity
GO:0016740 transferase activity 14 GO:0140110 transcription regulator activity 6 GO:0042393 histone binding 3 GO:0098772 molecular function regulator activity 3 GO:0060090 molecular adaptor activity 1
Localization
GO:0005634 nucleus 5 GO:0005694 chromosome 2
Pathway
R-HSA-4839726 Chromatin organization 11 R-HSA-168256 Immune System 9 R-HSA-162582 Signal Transduction 5 R-HSA-74160 Gene expression (Transcription) 5 R-HSA-1640170 Cell Cycle 3 R-HSA-1430728 Metabolism 2
Partners
BUBR1C11ORF46CDC20HP1RELASTAT3TP63
Complex memberships
APC/C (via BUBR1 interaction)

Evidence

Reading pass · 28 per-paper findings extracted from the source corpus
Year Finding Method Journal Conf PMIDs
2001 SETDB2 (CLLD8) was identified as containing a methyl-CpG binding domain, a preSET domain, and a SET domain, suggesting it is associated with methylation-mediated transcriptional repression. Sequence analysis and domain characterization of novel gene isolated from chromosome 13q14 Cancer research Low 11306461
2010 SETDB2 (CLLD8/KMT1F) functions as a histone H3K9 trimethyltransferase at interspersed repetitive elements and centromere-associated repeats, recruits heterochromatin protein 1 (HP1) to centromeres, and its depletion causes loss of CENP proteins and delayed mitosis, indicating a role in chromosome condensation and segregation. In vitro methyltransferase assay, ChIP, siRNA knockdown with mitosis phenotype readout, co-localization with HP1 and CENP proteins The Journal of biological chemistry High 20404330
2010 In zebrafish, Setdb2 restricts dorsal organizer territory and regulates left-right asymmetry by suppressing fgf8 expression; genetic epistasis showed that dominant-negative FGF receptor or fgf8 knockdown rescued Setdb2 morphant phenotypes, placing Setdb2 upstream of Fgf8 signaling. Morpholino knockdown, genetic epistasis (dominant-negative FGFR, fgf8 MO), in situ hybridization of organizer markers Proceedings of the National Academy of Sciences of the United States of America High 20133783
2014 Setdb2 expression is induced by type I interferon signaling during influenza virus infection and represses NF-κB target genes (including Cxcl1) by depositing H3K9me3 at their promoters; Setdb2 occupancy at the Cxcl1 promoter was demonstrated by ChIP, and hypomorphic Setdb2 mice showed increased neutrophil infiltration and altered susceptibility to bacterial superinfection. ChIP for Setdb2 and H3K9me3 at Cxcl1 promoter, gene-trap hypomorphic mouse model, neutrophil infiltration assay, bacterial superinfection model Nature immunology High 25419628
2014 In zebrafish, Setdb2 controls convergence and extension movements during gastrulation by transcriptionally regulating dvr1 (a TGF-β ligand); both overexpression and knockdown of Dvr1 phenocopied Setdb2 perturbation, placing Setdb2 upstream of Dvr1 in a non-cell-autonomous manner. Morpholino knockdown, genetic epistasis, in situ hybridization, overexpression rescue Developmental biology Medium 24892953
2016 SETDB2 acts as a positive regulator of glucocorticoid receptor (GR)-mediated gene activation in liver; SETDB2 facilitates GR chromatin enrichment and is required for glucocorticoid-dependent enhancer-promoter interactions that drive Insig2a induction, which in turn limits SREBP-driven lipid synthesis. ChIP, chromatin conformation (enhancer-promoter looping), siRNA knockdown, glucocorticoid treatment in liver, ob/ob mouse model Cell metabolism High 27568546
2016 SETDB2 overexpression in gastric cancer cells represses tumor suppressor genes WWOX and CADM1 through H3K9me3 deposition at their promoters; ChIP showed SETDB2 is recruited to these promoters and H3K9me3 levels correlated with SETDB2 expression. ChIP for H3K9me3 and SETDB2 at WWOX/CADM1 promoters, knockdown/overexpression, microarray Oncotarget Medium 27572307
2018 SETDB2 links the chimeric transcription factor E2A-PBX1 to cell-cycle dysregulation in ALL by directly silencing CDKN2C through H3K9 trimethylation at its promoter; SETDB2 is a direct transcriptional target of E2A-PBX1 and its knockdown enhances sensitivity to kinase and chromatin inhibitors. ChIP for H3K9me3 at CDKN2C promoter, shRNA knockdown, in vivo leukemia models, ChIP for E2A-PBX1 at SETDB2 locus Cell reports High 29694893
2018 In monocytes, Setdb2 levels correlate negatively with antifungal gene expression; Setdb2 mediates transcriptional repression of antifungal immune genes (Il1b, Tnf, Il6, Ifnb, Cxcl1, etc.) through H3K9 methylation at their promoters, contributing to susceptibility to Candida superinfection following bacterial infection. Lentivirus-mediated Setdb2 knockout and overexpression, ChIP for H3K9me3, murine superinfection model Cellular microbiology Medium 29749709
2019 In wound macrophages, SETDB2 trimethylates histone H3 at NF-κB binding sites on inflammatory cytokine gene promoters to suppress transcription; SETDB2 expression is regulated by IFNβ signaling, and myeloid-specific deletion impaired macrophage transition from inflammatory to reparative phenotype and disrupted xanthine oxidase/uric acid pathway regulation. Myeloid-specific conditional KO mouse, ChIP for H3K9me3 at NF-κB sites, cytokine profiling, wound healing assays Immunity High 31350176
2019 In an influenza-associated encephalopathy mouse model, Setdb2 is upregulated in brain tissue and deposits H3K9me3 at the Caveolin-1 promoter, repressing Caveolin-1 expression and thereby impairing blood-brain barrier integrity. ChIP for H3K9me3 at Caveolin-1 promoter, murine IAE model, qRT-PCR, immunofluorescence Scientific reports Medium 30670717
2020 SETDB2 interacts with and methylates ΔNp63α protein, stabilizing it, and upregulates transcription of Hedgehog pathway genes downstream of ΔNp63α to maintain breast cancer stem cells; restoring ΔNp63α expression rescued the breast cancer stem cell defect caused by SETDB2 knockdown. Co-immunoprecipitation, methylation assay, shRNA knockdown, mammosphere formation, in vivo tumor initiation International journal of biological sciences Medium 32549764
2020 AML1-ETO fusion protein epigenetically upregulates SETDB2 expression (shown by luciferase reporter and ChIP), and SETDB2 in turn promotes leukemic cell proliferation and clonality in t(8;21) AML. Dual luciferase reporter assay, ChIP, siRNA knockdown, CCK-8 and colony formation assays Cancer management and research Medium 32099474
2021 Coronavirus infection decreases SETDB2 in macrophages, reducing H3K9me3 at NF-κB binding sites on inflammatory gene promoters and thereby increasing NF-κB-mediated inflammation; IFNβ directly regulates SETDB2 via JAK1/STAT3 signaling, as blockade of this pathway alters SETDB2 levels and the inflammatory response. Myeloid-specific SETDB2 KO mouse, ChIP for H3K9me3 at NF-κB sites, JAK/STAT inhibition, human monocyte experiments with SARS-CoV-2 Proceedings of the National Academy of Sciences of the United States of America High 34479991
2021 Deletion of SETDB2 in hematopoietic cells promotes vascular inflammation, enhances atherosclerosis progression, increases monocyte population in plaques, and attenuates efferocytosis in Ldlr-KO mice receiving SETDB2-deficient bone marrow transplants. Bone marrow transfer to Ldlr-KO mice, single-cell RNA-seq, flow cytometry, macrophage efferocytosis assay JCI insight High 34003795
2022 SETDB2 suppresses NRF2 transcription in lung adenocarcinoma by recruiting H3K9me3 to the NRF2 promoter; loss of SETDB2 activates NRF2 and its downstream targets (NQO1, FTH1, ME1), promoting malignant phenotypes. ChIP-qPCR for H3K9me3 at NRF2 promoter, siRNA knockdown/overexpression, in vivo tumor assays, GSEA Cancer medicine Medium 36504353
2023 In aortic macrophages, IFNβ regulates SETDB2 expression through JAK/STAT signaling; SETDB2 then trimethylates H3K9 at TIMP1-3 gene promoters, suppressing TIMP1-3 transcription and leading to unregulated MMP activity during AAA development; myeloid-specific SETDB2 KO protected mice from AAA formation. scRNA-seq of human AAA tissue, myeloid-specific conditional KO mouse, ChIP for H3K9me3 at TIMP1-3 promoters, FDA-approved JAK inhibitor (Tofacitinib) treatment Annals of surgery High 37325923
2024 STAT3 is required for SETDB2 expression in macrophages but also functions as a binding partner of SETDB2 that inhibits its interaction with RELA/NF-κB, thereby paradoxically increasing NF-κB-mediated inflammatory gene expression; ATAC-seq showed SETDB2 suppresses chromatin accessibility at NF-κB-dependent gene promoters. ATAC-seq, RNA-seq in myeloid SETDB2-KO and STAT3-KO mice, Co-IP for STAT3/SETDB2/RELA interactions, wound macrophage isolation JCI insight High 39435663
2024 The annotated methyl-CpG-binding domain (MBD) of SETDB2, rather than binding DNA, instead interacts with a cysteine-rich domain of C11orf46, revealing it functions as a protein-protein interaction domain. Structural characterization (crystallography of MBD domain), protein interaction assays Structure High 38458157
2024 SETDB2 interacts with BUBR1 to promote CDC20 binding to BUBR1 and APC/C complex and facilitate CYCLIN B1 degradation, ensuring accurate chromosome segregation during mitosis; these functions are independent of SETDB2's histone methyltransferase activity. Co-immunoprecipitation of SETDB2/BUBR1/CDC20/APC/C, methyltransferase-dead mutant, CYCLIN B1 degradation assay, mitosis phenotype readout FEBS open bio Medium 38151757
2024 Setdb2 knockout in macrophages promotes M2 polarization through upregulation of the PI3K/Akt signaling pathway; PI3K inhibitor LY294002 nullified the effect of Setdb2 on macrophage activation, placing Setdb2 upstream of PI3K/Akt in macrophage polarization. Conditional KO mouse, RNA-seq, western blot for PI3K/Akt pathway, PI3K inhibitor rescue, flow cytometry Biochemical and biophysical research communications Medium 38905784
2025 Setdb2 regulates trained immunity through two distinct mechanisms: (1) positively regulating glycolytic and inflammatory genes via enhancer-promoter looping independently of its enzymatic activity, and (2) repressing interferon response genes through increased H3K9me3 at promoters; pathogenic training activates both, while sterile inflammatory stimuli activate only the chromatin-looping mechanism. Genetic mouse models, genomic analysis (ChIP-seq, chromatin conformation), enzymatic-dead mutant, β-glucan and Western diet/oxLDL training models bioRxivpreprint Medium 40166182
2025 In podocytes, SETDB2 directly enhances H3K9me3 at the Smad3 promoter, repressing SMAD3 expression and activation to preserve podocyte function; TCF21, a transcription factor downregulated in diabetic kidney disease, was identified as a direct upstream regulator of Setdb2 by binding to its promoter and activating transcription. Podocyte-specific KO and OE mouse models, ChIP for H3K9me3 at Smad3 promoter, ChIP for TCF21 at Setdb2 promoter, DKD mouse models Advanced science Medium 41316884
2025 In fibroblasts, TNF-α increases SETDB2 expression via a JAK1,3/STAT3 signaling pathway, and elevated SETDB2 represses myofibroblast differentiation genes; fibroblast-specific SETDB2 knockdown or JAK1,3/STAT3 inhibition improved diabetic wound repair. Human tissue samples, transgenic murine models, JAK inhibitor treatment, fibroblast-specific KD, TNF-α receptor blockade, macrophage supernatant co-culture JCI insight Medium 41277557
2025 In esophageal squamous cell carcinoma, SETDB2 silences TFRC (transferrin receptor) through H3K9me3 at two distinct sites within its promoter, thereby modulating cellular iron metabolism via the TFRC-STEAP3-DMT1 axis; TFRC knockdown rescued proliferation changes caused by SETDB2 knockdown. ChIP for H3K9me3 at TFRC promoter, siRNA KD/rescue, Fe2+ and ROS measurement, in vitro and in vivo functional assays Biochemical pharmacology Medium 40645600
2025 In trigeminal ganglion neurons, upregulated SETDB2 deposits H3K9me3 at the Ide promoter, blocking KLF4 transcription factor binding and suppressing IDE expression, which impairs degradation of CGRP; reducing SETDB2 in TG neurons alleviated migraine-like pain behaviors in mice. Nitroglycerin chronic migraine mouse model, ChIP for H3K9me3 and KLF4 at Ide promoter, SETDB2 KD in TG neurons, CGRP degradation assay, pain behavioral readout Cell reports Medium 41880325
2026 SETDB2 silences SRSF1 via H3K9me3 at its promoter, reducing functional SHP-1 spliceosome formation, which leads to constitutive JAK/STAT3 activation; SETDB2 also promotes M2 polarization of tumor-associated macrophages and inhibits effector T cells, driving immunosuppression and immunotherapy resistance in hepatocellular carcinoma. RNA-seq and proteomics in PDX model, ChIP for H3K9me3 at SRSF1 promoter, SETDB2 KO, CD8+ T cell infiltration assay, splicing analysis of SHP-1 Oncogene Medium 41946995
2026 SETDB2 drives M2-like macrophage polarization in knee osteoarthritis through H3K9me3-mediated repression of ALPK1; SETDB2 knockdown reduced H3K9me3 enrichment at ALPK1 and upregulated ALPK1, and ALPK1 overexpression reversed the beneficial effects of SETDB2-overexpressing macrophages on chondrocytes. KOA mouse model, ChIP-qPCR for H3K9me3 at ALPK1 locus, SETDB2 KO/OE, ALPK1 OE rescue, bulk RNA-seq, flow cytometry FASEB journal Medium 41482828

Source papers

Stage 0 corpus · 34 papers · ranked by NIH iCite citations
Year Title Journal Citations PMID
2019 The Histone Methyltransferase Setdb2 Modulates Macrophage Phenotype and Uric Acid Production in Diabetic Wound Repair. Immunity 123 31350176
2014 The methyltransferase Setdb2 mediates virus-induced susceptibility to bacterial superinfection. Nature immunology 119 25419628
2001 Cloning and characterization of CLLD6, CLLD7, and CLLD8, novel candidate genes for leukemogenesis at chromosome 13q14, a region commonly deleted in B-cell chronic lymphocytic leukemia. Cancer research 83 11306461
2019 Emerging roles of H3K9me3, SETDB1 and SETDB2 in therapy-induced cellular reprogramming. Clinical epigenetics 67 30850015
2010 CLLD8/KMT1F is a lysine methyltransferase that is important for chromosome segregation. The Journal of biological chemistry 66 20404330
2016 SETDB2 Links Glucocorticoid to Lipid Metabolism through Insig2a Regulation. Cell metabolism 56 27568546
2010 Setdb2 restricts dorsal organizer territory and regulates left-right asymmetry through suppressing fgf8 activity. Proceedings of the National Academy of Sciences of the United States of America 44 20133783
2021 Coronavirus induces diabetic macrophage-mediated inflammation via SETDB2. Proceedings of the National Academy of Sciences of the United States of America 31 34479991
2018 SETDB2 Links E2A-PBX1 to Cell-Cycle Dysregulation in Acute Leukemia through CDKN2C Repression. Cell reports 29 29694893
2016 Oncogenic roles of the SETDB2 histone methyltransferase in gastric cancer. Oncotarget 28 27572307
2021 Deficiency of histone lysine methyltransferase SETDB2 in hematopoietic cells promotes vascular inflammation and accelerates atherosclerosis. JCI insight 27 34003795
2014 Setdb2 controls convergence and extension movements during zebrafish gastrulation by transcriptional regulation of dvr1. Developmental biology 19 24892953
2023 The Histone Methyltransferase SETDB2 Modulates Tissue Inhibitors of Metalloproteinase-Matrix Metalloproteinase Activity During Abdominal Aortic Aneurysm Development. Annals of surgery 15 37325923
2019 Abrogated Caveolin-1 expression via histone modification enzyme Setdb2 regulates brain edema in a mouse model of influenza-associated encephalopathy. Scientific reports 15 30670717
2015 Left-Right Axis Differentiation and Functional Lateralization: a Haplotype in the Methyltransferase Encoding Gene SETDB2 Might Mediate Handedness in Healthy Adults. Molecular neurobiology 14 26572639
2024 The STAT3/SETDB2 axis dictates NF-κB-mediated inflammation in macrophages during wound repair. JCI insight 11 39435663
2020 SETDB2 promoted breast cancer stem cell maintenance by interaction with and stabilization of ΔNp63α protein. International journal of biological sciences 11 32549764
2015 A functional AT/G polymorphism in the 5'-untranslated region of SETDB2 in the IgE locus on human chromosome 13q14. Genes and immunity 7 26378653
2023 THE CRITICAL ROLE OF THE HISTONE MODIFICATION ENZYME SETDB2 IN THE PATHOGENESIS OF ACUTE RESPIRATORY DISTRESS SYNDROME. Shock (Augusta, Ga.) 6 37195726
2017 The SETDB2 locus: evidence for a genetic link between handedness and atopic disease. Heredity 6 29234167
2022 Histone lysine methyltransferase SETDB2 suppresses NRF2 to restrict tumor progression and modulates chemotherapy sensitivity in lung adenocarcinoma. Cancer medicine 5 36504353
2020 Oncogenic Roles Of A Histone Methyltransferase SETDB2 In AML1-ETO Positive AML. Cancer management and research 4 32099474
2018 Bacteria-induced susceptibility to Candida albicans super-infection in mice via monocyte methyltransferase Setdb2. Cellular microbiology 4 29749709
2024 Downregulation of Setdb2 promotes alternative activation of macrophages via the PI3K/Akt pathway to attenuate NAFLD after sleeve gastrectomy. Biochemical and biophysical research communications 3 38905784
2025 Setdb2 Regulates Inflammatory Trigger-Induced Trained Immunity of Macrophages Through Two Different Epigenetic Mechanisms. bioRxiv : the preprint server for biology 2 40166182
2026 SETDB2 Alleviates Knee Osteoarthritis Progression by Promoting M2-Like Macrophage Polarization via Targeting ALPK1. FASEB journal : official publication of the Federation of American Societies for Experimental Biology 1 41482828
2025 Setdb2 Regulates Inflammatory Trigger-Induced Trained Immunity of Macrophages Through Two Different Epigenetic Mechanisms. Research square 1 40502770
2025 SETDB2 Mitigates Podocyte Dysfunction in Diabetic Kidney Disease Through Epigenetic Silencing of SMAD3. Advanced science (Weinheim, Baden-Wurttemberg, Germany) 1 41316884
2024 One form and two functions: MBD of SETDB2 is a protein-interacting domain. Structure (London, England : 1993) 1 38458157
2026 SETDB2-mediated transcriptional repression of IDE in sensory neurons promotes migraine-like pain behaviors in mice. Cell reports 0 41880325
2026 SETDB2 induces abnormal SHP-1 splicing and promotes immunosuppression in hepatocellular carcinoma. Oncogene 0 41946995
2025 SETDB2 participates in iron metabolism in esophageal squamous cell carcinoma via H3K9me3-mediated TFRC silencing. Biochemical pharmacology 0 40645600
2025 TNF-α represses fibroblast to myofibroblast transition through the histone methyltransferase Setdb2. JCI insight 0 41277557
2024 SETDB2 interacts with BUBR1 to induce accurate chromosome segregation independently of its histone methyltransferase activity. FEBS open bio 0 38151757